A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma

被引:8
|
作者
Braunstein, Marc [1 ]
Weltz, Jonathan [2 ]
Davies, Faith [3 ]
机构
[1] NYU, Long Isl Sch Med, Dept Med, Div Oncol Hematol, New York, NY USA
[2] NYU, Perlmutter Canc Ctr, New York, NY USA
[3] NYU, Grossman Sch Med, Div Hematol Oncol, Dept Med, New York, NY USA
关键词
Multiple myeloma; immunotherapies; monoclonal antibodies; antibody-drug conjugates; bispecific antibodies; car-t cells; T-CELL THERAPY; OPEN-LABEL; TUMOR MICROENVIRONMENT; MONOCLONAL-ANTIBODIES; PLUS POMALIDOMIDE; PD-1; BLOCKADE; DARATUMUMAB; DEXAMETHASONE; MULTICENTER; BCMA;
D O I
10.1080/17474086.2021.1909469
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Survival in multiple myeloma (MM) has improved due to the ongoing revolution of therapeutic approaches. Nevertheless, many patients relapse, and additional novel approaches are required to prolong remissions and prevent disease progression. Areas Covered Considering the success of monoclonal antibodies (mAbs) against CD38 and SLAMF7 in relapsed/refractory MM (R/R MM), additional antigens expressed on malignant plasma cells are being investigated as treatment targets. Among these, many trials are focusing on B cell maturation antigen (BCMA), using either antibody-drug conjugates (ADCs), bispecific T cell engagers (TCE), or chimeric antigen receptor T cells (CAR-T). Other potential targets include the myeloma markers CD138, GPRC5D, FcRH5, the plasma cell differentiating factors APRIL, TACI and BAFF, and the immune checkpoint proteins CD47 and TIGIT. Additionally, novel immunomodulatory Cereblon E3 Ligase Modulators (CELMoDs) offer the potential to overcome resistance to conventional immunomodulatory agents. Based upon PubMed and abstract searches primarily from the past 4 years, here we review the data supporting novel immunotherapies for R/R MM. Expert opinion Overcoming disease resistance remains a challenge in R/R MM. Novel therapeutic approaches targeting MM antigens and/or enhancing immune cell function offer the potential to prolong survival and are actively being investigated in clinical trials.
引用
收藏
页码:377 / 389
页数:13
相关论文
共 50 条
  • [1] The emerging therapeutic landscape of relapsed/refractory multiple myeloma
    Tanenbaum, Benjamin
    Miett, Timothy
    Patel, Shyam A.
    ANNALS OF HEMATOLOGY, 2023, 102 (01) : 1 - 11
  • [2] Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma
    Parekh, Deevyashali S.
    Tiger, Yun Kyoung Ryu
    Jamouss, Kevin Tony
    Hassani, Justin
    Bou Zerdan, Maroun
    Raza, Shahzad
    CANCERS, 2024, 16 (17)
  • [3] New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma
    Abdallah, Nadine
    Kumar, Shaji K.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2024, 38 (02) : 511 - 532
  • [4] Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
    Chim, C. S.
    Kumar, S. K.
    Orlowski, R. Z.
    Cook, G.
    Richardson, P. G.
    Gertz, M. A.
    Giralt, S.
    Mateos, M. V.
    Leleu, X.
    Anderson, K. C.
    LEUKEMIA, 2018, 32 (02) : 252 - 262
  • [5] Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma
    Dimopoulos, Meletios-Athanasios
    Richardson, Paul
    Lonial, Sagar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07) : 460 - 473
  • [6] Therapeutic progress in relapsed/refractory multiple myeloma
    Chen, Qi
    Zhang, Min
    Zheng, Shan
    Tong, Yuxin
    Tan, Yamin
    ANNALS OF HEMATOLOGY, 2024, 103 (06) : 1833 - 1841
  • [7] Novel Drug Combinations for the Management of Relapsed/Refractory Multiple Myeloma
    Usmani, Saad Z.
    Lonial, Sagar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S71 - S77
  • [8] Management of Relapsed/Refractory Multiple Myeloma
    Callander, Natalie S.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (5.5): : 552 - 555
  • [9] Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma
    Sheikh, Semira
    Lebel, Eyal
    Trudel, Suzanne
    FUTURE ONCOLOGY, 2020, 16 (34) : 2783 - 2798
  • [10] Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
    Podar, Klaus
    Leleu, Xavier
    CANCERS, 2021, 13 (20)